SVB Leerink Maintains Outperform on Zai Lab, Lowers Price Target to $102
SVB Leerink analyst Jonathan Chang maintains Zai Lab (NASDAQ:ZLAB) with a Outperform and lowers the price target from $194 to $102.
Recap: Zai Lab FY Earnings
Zai Lab (NASDAQ:ZLAB) reported its FY earnings results on Tuesday, March 1, 2022 at 04:30 PM.
Here's what investors need to know about the announcement.
Earnings
Zai Lab missed estimated earnings by 35.76%, reporting an EPS of $-2.24 versus an estimate of $-1.65.
The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More
Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that encompassed the JPM Healthcare conference.
58 Biggest Movers From Yesterday
Gainers
Adagio Therapeutics, Inc. (NASDAQ: ADGI) shares jumped 123.3% to settle at $14.18 on Thursday after traders circulated rumors of a reiterated Buy rating and $46 price target from Jefferies.
Zai Lab Announced China NMPA Approves NUZYRA as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections
Zai Lab Limited (NASDAQ: ZLAB), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that the China National Medical Products Administration (NMPA) has approved its New Drug Application (NDA) for NUZYRA® (omadacycline), a novel antibiotic with both oral and intravenous (IV) fo
46 Biggest Movers From Yesterday
Gainers
Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) gained 34.1% to settle at $12.58 on Wednesday.
36 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Nxt-ID, Inc. (NASDAQ: NXTD) shares gained 28.9% to $3.21 after the company said it was awarded U.S. General Services Administration contract to distribute personal emergency response systems to Federal, State and Local government purchasers.
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date period to 45. This is just one short of NME approvals received for the same period last year.